Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review
![](/report_cover/1896/correvio-pharma-corp-corv-financial-n-strategic-swot-analysis-review_en.gif)
Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Correvio Pharma Corp (Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). It has collaborations with other pharmaceutical companies to commercialize products which include Zevtera, a cephalosporin antibiotic indicated for the treatment of community and hospital acquired pneumonia and Xydalba, a second generation semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections. Correvio's pipeline product includes Trevyent a drug device combination for pulmonary arterial hypertension. The company has offices in Canada, the US, Switzerland, France and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.
Correvio Pharma Corp Key Recent Developments
Nov 14,2019: Correvio reports third quarter 2019 financial results
Aug 14,2019: Correvio reports second quarter 2019 financial results
May 08,2019: Correvio reports first quarter 2019 financial results
Mar 13,2019: Correvio reports fourth quarter and full year 2018 financial results
Jan 02,2019: Correvio announces chief executive officer succession plan and other board and executive changes
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Correvio Pharma Corp (Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). It has collaborations with other pharmaceutical companies to commercialize products which include Zevtera, a cephalosporin antibiotic indicated for the treatment of community and hospital acquired pneumonia and Xydalba, a second generation semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections. Correvio's pipeline product includes Trevyent a drug device combination for pulmonary arterial hypertension. The company has offices in Canada, the US, Switzerland, France and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.
Correvio Pharma Corp Key Recent Developments
Nov 14,2019: Correvio reports third quarter 2019 financial results
Aug 14,2019: Correvio reports second quarter 2019 financial results
May 08,2019: Correvio reports first quarter 2019 financial results
Mar 13,2019: Correvio reports fourth quarter and full year 2018 financial results
Jan 02,2019: Correvio announces chief executive officer succession plan and other board and executive changes
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Correvio Pharma Corp - Key Facts
Correvio Pharma Corp - Key Employees
Correvio Pharma Corp - Key Employee Biographies
Correvio Pharma Corp - Major Products and Services
Correvio Pharma Corp - History
Correvio Pharma Corp - Company Statement
Correvio Pharma Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Correvio Pharma Corp - Business Description
Correvio Pharma Corp - SWOT Analysis
SWOT Analysis - Overview
Correvio Pharma Corp - Strengths
Correvio Pharma Corp - Weaknesses
Correvio Pharma Corp - Opportunities
Correvio Pharma Corp - Threats
Correvio Pharma Corp - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Correvio Pharma Corp, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 14, 2019: Correvio reports third quarter 2019 financial results
Aug 14, 2019: Correvio reports second quarter 2019 financial results
May 08, 2019: Correvio reports first quarter 2019 financial results
Mar 13, 2019: Correvio reports fourth quarter and full year 2018 financial results
Jan 02, 2019: Correvio announces chief executive officer succession plan and other board and executive changes
Aug 14, 2018: Correvio announces second quarter 2018 financial results
May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV
May 15, 2018: Correvio Announces First Quarter 2018 Financial Results
May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
Apr 06, 2018: Cardiome Announces Amendment To Term Loan Agreement With Crg-Managed Funds
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Correvio Pharma Corp - Key Facts
Correvio Pharma Corp - Key Employees
Correvio Pharma Corp - Key Employee Biographies
Correvio Pharma Corp - Major Products and Services
Correvio Pharma Corp - History
Correvio Pharma Corp - Company Statement
Correvio Pharma Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Correvio Pharma Corp - Business Description
Correvio Pharma Corp - SWOT Analysis
SWOT Analysis - Overview
Correvio Pharma Corp - Strengths
Correvio Pharma Corp - Weaknesses
Correvio Pharma Corp - Opportunities
Correvio Pharma Corp - Threats
Correvio Pharma Corp - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Correvio Pharma Corp, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Nov 14, 2019: Correvio reports third quarter 2019 financial results
Aug 14, 2019: Correvio reports second quarter 2019 financial results
May 08, 2019: Correvio reports first quarter 2019 financial results
Mar 13, 2019: Correvio reports fourth quarter and full year 2018 financial results
Jan 02, 2019: Correvio announces chief executive officer succession plan and other board and executive changes
Aug 14, 2018: Correvio announces second quarter 2018 financial results
May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV
May 15, 2018: Correvio Announces First Quarter 2018 Financial Results
May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
Apr 06, 2018: Cardiome Announces Amendment To Term Loan Agreement With Crg-Managed Funds
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Correvio Pharma Corp, Key Facts
Correvio Pharma Corp, Key Employees
Correvio Pharma Corp, Key Employee Biographies
Correvio Pharma Corp, Major Products and Services
Correvio Pharma Corp, History
Correvio Pharma Corp, Subsidiaries
Correvio Pharma Corp, Key Competitors
Correvio Pharma Corp, Ratios based on current share price
Correvio Pharma Corp, Annual Ratios
Correvio Pharma Corp, Annual Ratios (Cont...1)
Correvio Pharma Corp, Annual Ratios (Cont...2)
Correvio Pharma Corp, Interim Ratios
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Correvio Pharma Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Correvio Pharma Corp, Key Facts
Correvio Pharma Corp, Key Employees
Correvio Pharma Corp, Key Employee Biographies
Correvio Pharma Corp, Major Products and Services
Correvio Pharma Corp, History
Correvio Pharma Corp, Subsidiaries
Correvio Pharma Corp, Key Competitors
Correvio Pharma Corp, Ratios based on current share price
Correvio Pharma Corp, Annual Ratios
Correvio Pharma Corp, Annual Ratios (Cont...1)
Correvio Pharma Corp, Annual Ratios (Cont...2)
Correvio Pharma Corp, Interim Ratios
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Correvio Pharma Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Correvio Pharma Corp, Performance Chart (2014 - 2018)
Correvio Pharma Corp, Ratio Charts
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
COMPANIES MENTIONED
Sanofi-Aventis Canada Inc
H. Lundbeck AS
Gilead Sciences Inc
AstraZeneca Canada Inc
ASKA Research
Correvio Pharma Corp, Performance Chart (2014 - 2018)
Correvio Pharma Corp, Ratio Charts
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
COMPANIES MENTIONED
Sanofi-Aventis Canada Inc
H. Lundbeck AS
Gilead Sciences Inc
AstraZeneca Canada Inc
ASKA Research